NASDAQ : ELTX
Elicio Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.69 USD (Oct 30, 2026, 3:05 PM EDT) · Market cap 44.42M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 14.23M | 12.81M | 11.33M | 11.90M | 5.63M | 7.54M |
| Research & Development | 23.69M | 24.90M | 33.66M | 23.85M | 18.10M | 17.93M |
| Operating Expenses | 37.92M | 37.71M | 44.99M | 35.74M | 23.73M | 25.47M |
| Operating Income | -37.92M | -37.71M | -44.99M | -35.74M | -23.73M | -25.47M |
| Interest Expense | -1.58M | -1.13M | -455.00K | -1.06M | -3.60M | -876.44K |
| Interest & Investment Income | 693.00K | 776.00K | 777.00K | 373.00K | 65.00K | 3.39K |
| Currency Exchange Gain (Loss) | 14.00K | 151.00K | 204.00K | |||
| Other Non Operating Income (Expenses) | 950.00K | -1.92M | -7.39M | 427.00K | -945.00K | -52.96K |
| EBT Excluding Unusual Items | -37.84M | -39.99M | -51.90M | -35.80M | -28.21M | -26.40M |
| Gain (Loss) on Sale of Assets | 3.00K | |||||
| Other Unusual Items | 415.00K | 605.00K | 2.00K | |||
| Pretax Income | -37.84M | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
| Net Income | -37.84M | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
| Net Income to Common | -37.84M | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
| Shares Outstanding (Basic) | 17.42M | 15.31M | 12.20M | 5.06M | 316.00K | 15.28M |
| Shares Outstanding (Diluted) | 17.42M | 15.31M | 12.20M | 5.06M | 316.00K | 15.28M |
| EPS (Basic) | -2.17 | -2.58 | -4.25 | -6.96 | -89.27 | -1.73 |
| EPS (Diluted) | -2.17 | -2.58 | -4.25 | -6.96 | -89.27 | -1.73 |
| Free Cash Flow | -37.71M | -36.97M | -37.16M | -32.76M | -22.83M | -24.46M |
| Free Cash Flow Per Share | -2.17 | -2.41 | -3.04 | -6.48 | -72.26 | -1.60 |
| EBITDA | -37.74M | -37.51M | -44.66M | -35.36M | -23.34M | -25.22M |
| D&A For EBITDA | 180.00K | 204.00K | 321.00K | 382.00K | 390.00K | 251.45K |
| EBIT | -37.92M | -37.71M | -44.99M | -35.74M | -23.73M | -25.47M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 23.48M | 18.56M | 17.62M | 12.89M | 6.16M | 9.28M |
| Cash & Short-Term Investments | 23.48M | 18.56M | 17.62M | 12.89M | 6.16M | 9.28M |
| Prepaid Expenses | 1.57M | 555.00K | 1.65M | 2.43M | 2.27M | 177.11K |
| Restricted Cash | 1.18M | 722.00K | 1.64M | 148.26K | ||
| Other Current Assets | 439.00K | 193.00K | 243.00K | 300.00K | 648.00K | 757.85K |
| Total Current Assets | 25.48M | 19.31M | 20.69M | 16.35M | 10.72M | 10.36M |
| Property, Plant & Equipment | 4.50M | 5.08M | 6.19M | 7.28M | 8.50M | 887.37K |
| Other Long-Term Assets | 1.34M | 1.47M | 1.30M | 3.52M | 3.45M | 3.57M |
| Total Assets | 31.33M | 25.86M | 28.18M | 27.15M | 22.66M | 14.81M |
| Accounts Payable | 839.00K | 672.00K | 1.04M | 4.37M | 2.81M | 1.68M |
| Accrued Expenses | 7.29M | 6.43M | 8.41M | 3.76M | 1.94M | 2.32M |
| Short-Term Debt | 11.80M | |||||
| Current Portion of Leases | 1.07M | 1.01M | 901.00K | 910.00K | 692.00K | |
| Other Current Liabilities | 1.17M | 719.00K | 1.44M | 3.09M | ||
| Total Current Liabilities | 9.20M | 8.11M | 11.52M | 9.76M | 6.87M | 18.88M |
| Long-Term Debt | 9.54M | 9.41M | 20.03M | |||
| Long-Term Leases | 3.54M | 4.09M | 5.11M | 6.01M | 6.79M | |
| Other Long-Term Liabilities | 1.12M | 2.62M | 2.83M | 11.00K | 92.00K | 29.75K |
| Total Liabilities | 23.39M | 24.23M | 39.49M | 15.77M | 13.75M | 18.91M |
| Common Stock | 219.00K | 178.00K | 110.00K | 96.00K | 3.00K | 171.43K |
| Additional Paid-In Capital | 261.71M | 235.41M | 183.00M | 153.83M | 4.86M | 4.09M |
| Retained Earnings | -253.71M | -233.67M | -194.10M | -142.20M | -107.01M | -78.80M |
| Treasury Stock | -150.00K | -150.00K | -150.00K | -150.00K | ||
| Comprehensive Income & Other | -126.00K | -127.00K | -175.00K | -197.00K | ||
| Total Common Equity | 7.94M | 1.64M | -11.31M | 11.37M | -102.14M | -74.54M |
| Shareholders' Equity | 7.94M | 1.64M | -11.31M | 11.37M | 8.91M | -4.10M |
| Total Liabilities & Equity | 31.33M | 25.86M | 28.18M | 27.15M | 22.66M | 14.81M |
| Total Debt | 14.15M | 14.51M | 26.04M | 6.92M | 7.48M | 11.80M |
| Net Cash (Debt) | 9.33M | 4.05M | -8.42M | 5.98M | -1.32M | -2.52M |
| Net Cash Per Share | 0.54 | 0.26 | -0.69 | 1.18 | -4.19 | -0.16 |
| Filing Date Shares Outstanding | 26.28M | 18.40M | 15.94M | 10.22M | 17.70M | 17.14M |
| Total Common Shares Outstanding | 21.90M | 17.80M | 11.03M | 9.60M | 17.70M | 17.14M |
| Working Capital | 16.28M | 11.20M | 9.17M | 6.59M | 3.85M | -8.52M |
| Book Value Per Share | 0.36 | 0.09 | -1.03 | 1.18 | -5.77 | -4.35 |
| Tangible Book Value | 7.94M | 1.64M | -11.31M | 11.37M | -102.14M | -74.54M |
| Tangible Book Value Per Share | 0.36 | 0.09 | -1.03 | 1.18 | -5.77 | -4.35 |
| Machinery | 1.92M | 1.92M | 1.90M | 1.82M | 2.15M | |
| Leasehold Improvements | 132.00K | 132.00K | 132.00K | 132.00K | 124.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -37.84M | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
| Depreciation & Amortization | 1.14M | 1.13M | 1.18M | 1.17M | 1.06M | 251.45K |
| Other Amortization | 310.00K | 217.00K | 75.00K | |||
| Loss (Gain) From Sale of Assets | -3.00K | 105.00K | 4.00K | |||
| Stock-Based Compensation | 3.27M | 2.70M | 1.45M | 1.18M | 579.00K | 617.76K |
| Other Operating Activities | -1.06M | 2.02M | 8.17M | 104.00K | 4.54M | 720.01K |
| Change in Accounts Payable | -3.03M | -366.00K | -3.33M | 23.00K | 1.12M | 30.23K |
| Change in Other Net Operating Assets | -488.00K | -3.08M | 7.29M | -80.00K | -1.27M | 842.21K |
| Operating Cash Flow | -37.69M | -36.95M | -37.07M | -32.69M | -22.18M | -23.94M |
| Capital Expenditures | -16.00K | -16.00K | -87.00K | -66.00K | -654.00K | -525.36K |
| Sale of Property, Plant & Equipment | 3.00K | 34.00K | ||||
| Investing Cash Flow | -16.00K | -16.00K | -84.00K | -32.00K | -654.00K | -525.36K |
| Short-Term Debt Issued | 19.73M | 14.68M | ||||
| Long-Term Debt Issued | 9.87M | 10.00M | ||||
| Total Debt Issued | 9.87M | 19.73M | 10.00M | 14.68M | ||
| Net Debt Issued (Repaid) | 9.87M | 19.73M | 10.00M | 14.68M | ||
| Issuance of Common Stock | 38.97M | 26.83M | 23.14M | 7.13M | 82.00K | 205.66K |
| Repurchase of Common Stock | -150.00K | |||||
| Other Financing Activities | -549.00K | 21.64M | -437.99K | |||
| Financing Cash Flow | 38.97M | 36.70M | 42.32M | 38.61M | 21.20M | 19.39M |
| Foreign Exchange Rate Adjustments | -56.00K | 48.00K | 22.00K | |||
| Net Cash Flow | 1.21M | -225.00K | 5.19M | 5.89M | -1.63M | -5.07M |
| Free Cash Flow | -37.71M | -36.97M | -37.16M | -32.76M | -22.83M | -24.46M |
| Free Cash Flow Per Share | -2.17 | -2.41 | -3.04 | -6.48 | -72.26 | -1.60 |
| Levered Free Cash Flow | -22.32M | -21.45M | -23.63M | -16.94M | -20.49M | -12.51M |
| Unlevered Free Cash Flow | -21.64M | -20.96M | -23.42M | -16.28M | -18.24M | -11.96M |
| Change in Working Capital | -3.51M | -3.44M | 3.96M | -57.00K | -150.00K | 872.43K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 42.31M | 139.10M | 54.96M | 80.11M | ||
| Enterprise Value | 32.98M | 133.55M | 55.00M | 72.42M | ||
| Last Close Price | 1.68 | 7.96 | 5.10 | 8.34 | ||
| PB Ratio | 4.64 | 85.03 | -4.86 | 7.04 | ||
| P/TBV Ratio | 5.56 | 85.03 | 7.04 | |||
| Debt / Equity Ratio | 1.78 | 8.87 | -2.30 | 0.61 | 0.84 | -2.88 |
| Net Debt / Equity Ratio | -1.18 | -2.48 | -0.74 | -0.53 | 0.15 | -0.61 |
| Net Debt / EBITDA Ratio | 0.25 | 0.11 | -0.19 | 0.17 | -0.06 | -0.10 |
| Net Debt / FCF Ratio | 0.25 | 0.11 | -0.23 | 0.18 | -0.06 | -0.10 |
| Quick Ratio | 2.55 | 2.29 | 1.53 | 1.32 | 0.90 | 0.49 |
| Current Ratio | 2.77 | 2.38 | 1.80 | 1.68 | 1.56 | 0.55 |
| Return on Equity (ROE) | -774.56% | -170,157.38% | -346.95% | -1,170.93% | -430.76% | |
| Return on Assets (ROA) | -77.88% | -87.24% | -101.64% | -89.70% | -79.16% | -92.36% |
| Return on Capital Employed (ROCE) | -171.40% | -212.40% | -270.10% | -205.50% | -150.20% | 626.30% |
| Earnings Yield | -134.91% | -28.45% | -94.42% | -43.93% | ||
| FCF Yield | -85.40% | -26.58% | -67.60% | -40.89% | ||
| Buyback Yield / Dilution | -23.82% | -25.48% | -141.35% | -1,500.08% | 97.93% | -42.39% |